Elanco Animal Health Stock News

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 2.86% and 0.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for t

Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly re

Elanco Animal Health is coming off a record 2021 highlighted by strong earnings. The stock has been under pressure amid macro concerns including an ongoing Bird Flu outbreak with an uncertain impact o

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2022 financial results on Monday, May 9, 2022. Elanco will also conduct a conference c

Elanco Animal Health Incorporated (NYSE: ELAN) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have launched BiomEdit, a microbiome innovation company. BiomEdit will discover, develop and introduce

Elanco's Tangible Equity Units: Low Risk With A 6% Yield

During the recent session, Elanco Animal Health Incorporated (NYSE:ELAN)’s traded shares were 1.76 million, with the beta value of the company hitting 0.80. At the last check today, the stock’s price was $26.47, reflecting an intraday gain of 0.34% or $0.09. The 52-week high for the ELAN share is $37.49, that puts it down -41.63 … Elanco Animal Health Incorporated (NYSE: ELAN) Is Up 6.11% In A Month. Could There Be Any Hope That It Will Rise Soon? Read More »

Animal health companies Elanco Animal Health <>, IDEXX Laboratories <> and Zoetis <> have continued their recent losses as the U.S

SAN FRANCISCO , March 4, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Animal Feed Additives - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What''s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 17; Released: February 2022 Executive Pool: 8171 Companies: 272 - Players covered include ADDCON GmbH; Adisseo France SAS; Ajinomoto Co., Inc.; Alltech Inc.; Archer Daniels Midland Company; BASF SE; Cargill, Inc.; Chr. Hansen A/S; CJ CheilJedang Corp.; DelaconBiotechnik GmbH; DSM Nutritional Products; Eastman Chemical Company; Elanco Animal Health; Evonik Industries AG; Kemin Industries, Inc.; Lonza Group Ltd.; METEX NØØVISTAGO; Novozymes A/S; Novus International, Inc.; Nutreco N.V.; Pancosma SA; Phibro Animal Health Corporation; Provimi Holding B.V.; The Mosaic Company; Zoetis, Inc. and Others.

ELAN earnings call for the period ending December 31, 2021.

Elanco Animal Health Inc (NYSE: ELAN ) has reported Q4 EPS of $0.21 higher than $0.12 reported a year ago, surpassing analysts'' view of $0.17. Revenue was $1.11 billion, a decrease of 2% YY, unfavorably impacted by approximately $60 million of previously disclosed items that benefited Q4 FY20., beating the consensus of $1.10 billion. Pet Health''s revenue decreased 1% and was flat when excluding … Full story available on Benzinga.com

Elanco Animal Health Incorporated (ELAN) CEO Jeff Simmons on Q4 2021 Results - Earnings Call Transcript